NASDAQ:FBIO

Fortress Biotech Q4 2025 Earnings Results & Report

Fortress Biotech logo
$1.82 +0.11 (+6.43%)
Closing price 04:00 PM Eastern
Extended Trading
$1.82 0.00 (-0.11%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Fortress Biotech missed analyst expectations on both earnings and revenue in its Q4 2025 results, released March 31, 2026. The company reported EPS of -$0.21 versus the $0.11 consensus estimate, while revenue of $16.08 million fell short of the $26.17 million estimate by $10.09 million.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
After Market Closes
Conference Call Date
Conference Call
4:00 PM ET

Fortress Biotech EPS Results

Actual EPS
-$0.21
Consensus EPS
$0.11
Beat/Miss
Missed by -$0.32
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Fortress Biotech Revenue Results

Actual Revenue
$16.08 million
Expected Revenue
$26.17 million
Beat/Miss
Missed by -$10.09 million
YoY Revenue Growth
N/A

Earnings Documents

Fortress Biotech Q4 2025 Earnings FAQ

Fortress Biotech (NASDAQ:FBIO) reported earnings of -$0.21 per share for Q4 2025, missing the consensus estimate of $0.11. The report was announced on Tuesday, March 31, 2026.

Fortress Biotech reported revenue of $16.08 million for Q4 2025, against a consensus estimate of $26.17 million.

Fortress Biotech Earnings Headlines

Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
Fortress Biotech (FBIO) Projected to Post Earnings on Monday
See More Fortress Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fortress Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fortress Biotech and other key companies, straight to your email.

About Fortress Biotech

Fortress Biotech (NASDAQ:FBIO) is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiaries and affiliated companies. Its approach includes advancing drug candidates, acquiring or licensing development and commercialization rights, and building companies around selected products and programs.

The company’s activities span areas including oncology, dermatology, rare diseases and immunology. Its portfolio has included marketed dermatology medicines such as Qbrexza, Amzeeq and Zilxi, as well as investigational therapies at various stages of development. Products are commercialized primarily in the United States, directly or through affiliated companies.

Founded in 2006, Fortress Biotech has also established and supported subsidiary and affiliate companies to develop and commercialize therapeutic programs. The company is led by founder Lindsay A. Rosenwald, M.D., who serves as its chairman, president and chief executive officer.

View Fortress Biotech Profile